Artis BioSolutions, a San Diego-based advanced-therapies development and manufacturing company, said it has signed a definitive agreement to acquire Syngoi Technologies, a Bilbao, Spain-based biotech developing enzymatic approaches for manufacturing synthetic DNA. The deal is intended to add faster, lower-cost synthetic DNA manufacturing to Artis’ broader “gene-to-drug” platform spanning early development through clinical manufacturing.
After closing, Artis plans to establish a U.S. operating presence for Syngoi’s technology through its wholly owned Boston-area entity, Landmark Bio, aiming to integrate GMP synthetic DNA manufacturing with advanced-therapy development and manufacturing capabilities in the U.S. Syngoi’s European GMP-ready facilities in Bilbao will become part of Artis’ global footprint, with Artis also planning continued investment in Syngoi’s team and operations in the Basque Country. The transaction is expected to close in Q1 2026, subject to customary regulatory approvals and closing conditions, and financial terms were not disclosed.
KEY QUOTES:
“This acquisition enables customers to reduce fragmentation and inefficiency in gene-to-drug development by introducing innovative synthetic DNA manufacturing solutions… By combining Syngoi Technologies and Landmark Bio, we expand our ability to support advanced-therapy programs from early development through clinical manufacturing, while continuing to invest in the teams and regions driving innovation.”
Brian Neel, Co-Founder & CEO, Artis BioSolutions
“Joining Artis marks an important next chapter for Syngoi… together with Landmark Bio, this partnership significantly enhances our ability to deliver differentiated synthetic DNA solutions at a global scale. It strengthens our value proposition for customers and partners seeking reliable, high-quality platforms for advanced therapies.”
José Vicente Pons Andreu, Chief Executive Officer, Syngoi
“Since Syngoi’s inception, our scientific focus has been on developing a highly differentiated synthetic DNA platform designed to meet the most demanding requirements of advanced therapies.”
Julen Oyarzabal, Co-founder & Chief Scientific Officer, Syngoi
“Artis continues to execute on its strategy to build differentiated capabilities across advanced therapies development and manufacturing… We believe the addition of Syngoi meaningfully strengthens the platform for the global customer base and expands the solutions available to customers.”
Andrew Adams, Co-Founder & Managing Partner, Oak HC/FT
“Founded by our team, Syngoi has been supported through its growth to build a unique and differentiated synthetic DNA platform… Artis represents a strong strategic home for the business, and this combination positions the technology and team for long-term growth and impact.”
Damia Tormo, Managing Partner, Columbus Venture Partners
